Gemini Therapeutics (NASDAQ:GMTX) Sets New 12-Month High at $48.23

Gemini Therapeutics, Inc. (NASDAQ:GMTXGet Free Report) hit a new 52-week high during trading on Monday . The stock traded as high as $48.23 and last traded at $47.50, with a volume of 261019 shares trading hands. The stock had previously closed at $46.62.

Gemini Therapeutics Trading Down 2.5 %

The stock has a 50-day moving average of $37.29 and a two-hundred day moving average of $49.11. The firm has a market cap of $1.98 billion, a price-to-earnings ratio of -45.80 and a beta of -0.12.

About Gemini Therapeutics

(Get Free Report)

Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.

Featured Articles

Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with's FREE daily email newsletter.